Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business
BRISBANE, Calif., Feb. 14, 2013
BRISBANE, Calif., Feb. 14, 2013 /PRNewswire/ --InterMune, Inc. (NASDAQ: ITMN)
today announced that Sean P. Nolan has joined InterMune as Executive Vice
President and Chief Business Officer.
In this newly created position, Mr. Nolan will lead the creation and
establishment of InterMune's U.S. Commercial, Business Development and Global
Marketing groups. He will also oversee InterMune's Canadian operations and the
company's Manufacturing Operations and Supply Chain Management. Mr. Nolan will
report to Dan Welch, Chairman, Chief Executive Officer and President of
Mr. Welch said, "Sean will play a key role in InterMune's future as our
Esbriet sales continue to grow globally, we move closer to the anticipated
approval and launch of Esbriet in the United States and as we prepare to
develop our business.I am confident that Sean will provide the broad and deep
commercial and business experience, energy and drive that are essential during
this exciting period of growth and change for our company."
Mr. Nolan began his career at Abbott Laboratories in 1991 and during a period
of 13 years served in a variety of marketing and sales leadership positions.
In 2004, he joined Ovation Pharmaceuticals, a privately held specialty
pharmaceutical company focused on the development and commercialization of
therapies to treat rare diseases.At Ovation, Sean developed and implemented
the commercial strategies for the orphan drug pipeline and subsequently led
the organization's effort that resulted in FDA approval of the company's lead
compound.Ovation was acquired by the Danish pharmaceutical company, H.
Lundbeck in 2009.After leading the company integration process, Mr. Nolan
served as President of the newly created U.S. entity of Lundbeck. While at
Lundbeck, Mr. Nolan served on the board of the Tuberous Sclerosis Alliance,
and was co-chair of the Rare and Specialty Disease Committee of the
Pharmaceutical Research and Manufacturers of America (PhRMA).
Mr. Nolan joins InterMune from Reata Pharmaceuticals, where he most recently
served as Vice President and Chief Commercial Officer and built a commercial
operation to support the company's lead product.
InterMune is a biotechnology company focused on the research, development and
commercialization of innovative therapies in pulmonology and orphan fibrotic
diseases. In pulmonology, InterMune is focused on therapies for the treatment
of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung
disease.Pirfenidone, the only medicine approved for IPF anywhere in the
world, is approved for marketing by InterMune in the EU and Canada as
Esbriet^® and is currently in a Phase 3 clinical trial to support regulatory
registration in the United States. InterMune's research programs are focused
on the discovery of targeted, small-molecule therapeutics and biomarkers to
treat and monitor serious pulmonary and fibrotic diseases.For additional
information about InterMune and its R&D pipeline, please visit
SOURCE InterMune, Inc.
Contact: Jim Goff, InterMune, Inc., +1-415-466-2228, firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.